Literature DB >> 8640758

Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma.

G Ermak1, T Jennings, L Robinson, J S Ross, J Figge.   

Abstract

CD44 is a polymorphic family of cell surface proteoglycans and glycoproteins implicated in cell-cell and cell-matrix adhesion interactions, cell migration, and tumor metastasis. CD44 exists as a standard form and as multiple isoforms arising from alternative splicing of variant exons (termed v1-v10) encoding parts of the extracellular domain. We demonstrated previously that papillary thyroid carcinomas exhibit aberrant patterns of alternative CD44 mRNA splicing (G. Ermak et al., Cancer Res., 55: 4594-4598, 1995). In the present report, we use reverse transcription-PCR using a new high-performance polymerase formulation (Ex Taq; TaKaRa Shuzo Co., Ltd., Otsu, Japan) , followed by Southern hybridization, and demonstrate that alternative exon usage in papillary thyroid carcinomas is restricted primarily to exons v6, v7, v8, v9, and v10, with weak expression of v3. Expression of v8 is tightly linked to v9 and closely related to v10 expression. Also, v6 and v7 expression are closely related. Papillary thyroid cancers exhibit a marked increase in specific mRNA species containing combinations of exons v6 to v10. Several isoforms found in papillary cancers are not detectable in histologically normal tissue derived from the corresponding contralateral thyroid lobes. Examples include a 750-bp v6- and v7-containing PCR product and a 650-bp v8- and v9- containing PCR product. Finally, a novel 530-bp PCR product was discovered and shown to contain a subsegment from exon 4 joined to a subsegment of exon 13 (v8), followed by the complete sequence of exons 14 (v9) and 15 (v10). This novel isoform was present in both the papillary cancers and contralateral tissues. In conclusion, papillary thyroid cancers exhibit specific patterns of aberrant alternative CD44 splicing, distinguishing them from histologically normal thyroid tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640758

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Authors:  Marc-André Fortin; Alexei V Salnikov; Marika Nestor; Nils-Erik Heldin; Kristofer Rubin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-03       Impact factor: 9.236

2.  Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients.

Authors:  Subramanyam Dasari; Wudayagiri Rajendra; Lokanatha Valluru
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 3.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

4.  Involvement of osteopontin as a core protein in craniopharyngioma calcification formation.

Authors:  SongTao Qi; GuangLong Huang; Jun Pan; Jia Li; Xi'An Zhang; LuXiong Fang; BaoGuo Liu; Wei Meng; YongMing Zhang; XiaoJun Liu
Journal:  J Neurooncol       Date:  2009-11-10       Impact factor: 4.130

5.  Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Authors:  Elisa Menicali; Sonia Moretti; Pasquale Voce; Serena Romagnoli; Nicola Avenia; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-22       Impact factor: 5.555

6.  Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression.

Authors:  Balázs Bánky; Lívia Rásó-Barnett; Tamás Barbai; József Tímár; Péter Becságh; Erzsébet Rásó
Journal:  Mol Cancer       Date:  2012-11-14       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.